retatrutide phase 2 trial results obesity 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide FDA Approval Status 2026:

Flushing occurs in about 21% of users, headache in 12%

Body composition optimization in incretin therapy

Particular concerns exist for those with: Type 2 diabetes or pre-diabetes , due to opposing and unpredictable glycaemic effects Cardiovascular disease , given the potential for heart rate changes and fluid retention associated with GH Active malignancy , as GH stimulation is contraindicated in this setting Pregnancy or breastfeeding neither agent should be used during pregnancy or whilst breastfeeding

L-Carnitine is essential for transporting long-chain fatty acids across the mitochondrial membrane to support fat breakdown and energy generation

Guidelines on GLP-1, GIP, and Glucagon Agonists for Weight Management